[Background and prognostic factors of fungemia in patients with hematological disease].
Sixty-two episodes of fungemia which occurred in patients with hematological disorders between 1976 and 1996 in our hospital were analyzed with respect to background and prognostic factors. Forty-four of the patients were male and 18 were female. The underlying diseases were acute leukemia in 36 cases, chronic myelogenous leukemia in 9, malignant lymphoma in 9 and others in 8 cases. Trichosporon beigelii and Candida tropicalis were the most frequently isolated fungal pathogens. The prevalence of C. crusei increased while that of C. albicans decreased after 1988. Fuungemia frequently occurred in patients with following factors: 1) advanced disease, such as relapse of acute leukemia or malignant lymphoma or blast crisis of chronic myelogenous leukemia; 2) neutrophil count less than 100/microliter; 3) administration of antibiotics; 4) focal infection, gastrointestinal hemorrhage or urinary catheterization; and 5) isolation of causative organisms from surveillance cultures obtained just before the onset of fungemia. The mortality rate of patients with fungemia was 74%. Absence of hypotension, increased neutrophil count for a week after the onset of fungemia, and the intravenous administration of Amphotericin B (AMPH) were good prognostic factors. Fungemia frequently occurred in patients with advanced disease and had a very poor prognosis. These results emphasized the importance of isolation of fungus from surveillance cultures, early initiation of AMPH administration, and attempts to increase neutrophil counts with G-CSF and other measures for improving the prognosis of fungemia in patients with hematological disorders.
Ujiie
H
H
Fifth Department of Internal Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases.
Teshima
H
H
Maeda
T
T
Karasuno
T
T
Hiraoka
A
A
Nakamura
H
H
Masaoka
T
T
Yoshinaga
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D016469:Fungemia / Q000150:complications* / Q000401:mortality; D006801:Humans; D007938:Leukemia / Q000150:complications*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications; D008223:Lymphoma / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors